CSRT.L Regulatory News (CSRT)

19 January 2016

Consort Medical plc

Director Declaration

Pursuant to Listing Rule 9.6.14, Consort Medical plc ('the Company') gives notice that Jonathan Glenn, Chief Executive Officer of the Company, has been appointed a non-executive director of Tissue Regenix Group plc with effect from 19 January 2016.

Enquiries:

Consort Medical plc

John Ilett, Company Secretary 01442 867920

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.